Gemfibrozil

Gemfibrozil is antihyperlipidimic agent and reduces high levels of blood cholesterol. Gemfibrozil is the congener of the first generation fibric acid derivative clofibrate. It differs from clofibrate in its aliphatic chain and has two methyl groups rather than a chlorine atom on the phenoxy group.

Brands
GEMPID LOPID GEMZIL GEMZIL
Adult Dose
Dose: 600 mg
Single Dose: 600 (600)
Frequency: 12 hourly
Route: PO
Instructions:
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
. It is of Synthetic origin and belongs to Fibrates. It belongs to Lipid lowering agents pharmacological group on the basis of mechanism of action and also classified in Antilipemic Agent pharmacological group.The Molecular Weight of Gemfibrozil is 250.40. Its pKa is 4.7.
Contraindications
Gemfibrozil is contraindicated in conditions like Gall stones,Hepatic disease.
Effects
The severe or irreversible adverse effects of Gemfibrozil, which give rise to further complications include Myositic syndrome.Gemfibrozil produces potentially life-threatening effects which include Arrhythmias, Hypokalemia, Hypokalemia. which are responsible for the discontinuation of Gemfibrozil therapy.The symptomatic adverse reactions produced by Gemfibrozil are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Impotence, GI symptoms, Dermatitis, Gall stones.
Indications
Gemfibrozil is primarily indicated in conditions like Coronary heart disease, Hyperlipidaemias of type IIa, IIb, III and IV in patients who have not responded adequately to diet., Hyperlipoproteinaemia.
Interactions
Gemfibrozil is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementColestipol (HCl)DabrafenibStrong CYP3A4 inhibitors may increase levels of dabrafenib.consider alternate therapyFrusemide or FurosemidePhenytoin (Na)PioglitazonePitavastatinDue to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, Majorconcomitant administration of LIVALO with gemfibrozil should be avoided.RepaglinideGemfibrozil may increase the levels/effects of repaglinide.Rosiglitazone (Maleate)Gemfibrozil may increase the AUC of rosiglitazone.RosuvastatinGemfibrozil significantly increased rosuvastatin exposure. Combination therapy with Rosuvastatin and gemfibrozil should be avoided. If used, do not exceed Rosuvastatin10 mg once daily. TolbutamideTorasemideGemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Gemfibrozil is initiated, discontinued or dose changed.VORICONAZOLEGemfibrozil may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if gemfibrozil is initiated, discontinued or dose changed.Warfarin (Na)Gemfibrozil may enhance the anticoagulant effect of Warfarin. MajorThe significance of this interaction may warrant a 25% to 33% reduction in the dosage of Warfarin if Gemfibrozil is to be started. Monitor for toxic effects of Warfarin if Gemfibrozil is initiated/dose increased, or decreased effects if Gemfibrozil is discontinued/dose decreased. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
High level of AaminotransfracesDecrease in WBC or hemotocnt
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab, Caps Store in a well closed container, at room temperature, Below 30°C.
Warnings
Obtain periodic determination of serum lipid during administration of gemfibrozil. Withdraw the drug after 3 months if adequate response is not achieved. Perform periodic blood count during first 12 months of administration. Carefully monitor blood glucose level during therapy because it has a hyperglycemic effect. Avoid if creatinine clearance less than 30 ml/min.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.